Third hospital joins multicenter covid-19 bva-100® blood test study

New york, nov. 19, 2020 (globe newswire) -- daxor corporation (nyse mkt: dxr), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that wake forest baptist health will participate in an ongoing trial to treat patients hospitalized with covid-19 utilizing daxor's bva-100 (blood volume analyzer, "bva") technology. wake forest school of medicine is based in winston-salem, north carolina, and is set to enroll patients under the leadership of ashish k. khanna, md.
DXR Ratings Summary
DXR Quant Ranking